These include XGFR, a bispecific anti-IGF-IR/EGFR antibody that showed inhibition of tumor growth and enhanced immune activation in pancreatic cancer in vivo [39], and Istiratumab (MM-141) which co-targets IGF-IR and ErbB3. Here, IGF1R is linked to familial pancreatic carcinoma.